Yu Yang, Wang Zhe, Wang Lingling, Wang Qinghua, Tang Rongfan, Xiang Sutong, Deng Qirui, Hou Tingjun, Sun Huiyong
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, Jiangsu, P. R. China.
Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, P. R. China.
Research (Wash D C). 2023 Jun 19;6:0170. doi: 10.34133/research.0170. eCollection 2023.
Anaplastic lymphoma kinase (ALK), a tyrosine receptor kinase, has been proven to be associated with the occurrence of numerous malignancies. Although there have been already at least 3 generations of ALK inhibitors approved by FDA or in clinical trials, the occurrence of various mutations seriously attenuates the effectiveness of the drugs. Unfortunately, most of the drug resistance mechanisms still remain obscure. Therefore, it is necessary to reveal the bottom reasons of the drug resistance mechanisms caused by the mutations. In this work, on the basis of verifying the accuracy of 2 main kinds of binding free energy calculation methodologies [end-point method of Molecular Mechanics with Poisson-Boltzmann/Generalized Born and Surface Area (MM/PB(GB)SA) and alchemical method of Thermodynamic Integration (TI)], we performed a systematic analysis on the ALK systems to explore the underlying shared and specific drug resistance mechanisms, covering the one-drug-multiple-mutation and multiple-drug-one-mutation cases. Through conventional molecular dynamics (cMD) simulation in conjunction with MM/PB(GB)SA and umbrella sampling (US) in conjunction with contact network analysis (CNA), the resistance mechanisms of the in-pocket, out-pocket, and multiple-site mutations were revealed. Especially for the out-pocket mutation, a possible transfer chain of the mutation effect was revealed, and the reason why different drugs exhibited various sensitivities to the same mutation was also uncovered. The proposed mechanisms may be prevalent in various drug resistance cases.
间变性淋巴瘤激酶(ALK)是一种酪氨酸受体激酶,已被证明与多种恶性肿瘤的发生有关。尽管美国食品药品监督管理局(FDA)已批准或正在临床试验中至少有3代ALK抑制剂,但各种突变的出现严重削弱了药物的有效性。不幸的是,大多数耐药机制仍不清楚。因此,有必要揭示由突变引起的耐药机制的根本原因。在这项工作中,在验证了两种主要结合自由能计算方法[分子力学与泊松-玻尔兹曼/广义玻恩和表面积的端点法(MM/PB(GB)SA)和热力学积分的炼金术方法(TI)]准确性的基础上,我们对ALK系统进行了系统分析,以探索潜在的共同和特定耐药机制,涵盖单药多突变和多药单突变情况。通过结合MM/PB(GB)SA的传统分子动力学(cMD)模拟和结合接触网络分析(CNA)的伞形采样(US),揭示了口袋内、口袋外和多位点突变的耐药机制。特别是对于口袋外突变,揭示了突变效应可能的传递链,也揭示了不同药物对同一突变表现出不同敏感性的原因。所提出的机制可能在各种耐药情况下普遍存在。